Lupin’s partner ForDoz receives USFDA approval for doxorubicin hydrochloride liposome injection
Doxorubicin Hydrochloride Liposome Injection (RLD Doxil) had estimated annual sales of USD 42 million in the U.S. (IQVIA MAT May 2024)
Doxorubicin Hydrochloride Liposome Injection (RLD Doxil) had estimated annual sales of USD 42 million in the U.S. (IQVIA MAT May 2024)
Kwality Pharma already has registration of 20 molecules from the units and 20 are under registration
The inspection closed with five observations which were more of procedural changes with none of these related to data integrity
€ 6.6 million investment at Nantong site expands production capabilities for cell culture media
Selexipag is a prostacyclin receptor agonist indicated for the treatment of pulmonary arterial hypertension
Protein research is key to advancing our understanding of human biology and delivering on the promise of precision medicine
The approved ANDA is therapeutically equivalent to the reference listed drug product
This product will be manufactured at Lupin’s Pithampur facility in India
Aim of the collaboration is to develop mRNA platform technology, scale up and troubleshoot challenges in mRNA process optimization
Subscribe To Our Newsletter & Stay Updated